Regen BioPharma Inc (RGBP)

[OTCShotCaller]

RGBP Will Surpass ENZ*C Run To $1.00

ENZ*C ran to nearly $1 in February within 19 days of going PINK CURRENT!

RGBP will do FAR BETTER and here's WHY

ENZC had:
#1 (1) Patent only
#2 No FDA approval
#3 No licensing arrangements
#4 No partnerships
#5 No catalysts
#6 No PR releases
#7 No prospect of revenue (due to #2 & #3)
#8 No suggestion of Buy Out by CEO

RGBP has:
#1 20+ Patents worth $BILLIONS

#2 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine-"The Future of Medicine"

#3 Recent PR of FDA Approval for Clinical Trials

#4 Partnership: Received up front payment from Oncology Pharma for Patent Licensing; is NOW positioned to receive Quarterly Revenues for 15 YEARS!

#5 Going Pink Current within weeks = Instant buying capacity on dozens of brokerage platforms!

#6 CEO suggests Buy Out by filing an 8K to protect against a Hostile Take Over that specifically states "negotiations must be made direct" (in reference to himself).

IMPORTANT NOTE RELATIVE TO #4: Oncology Pharma closed yesterday 7/9/21 at $27.39 UP $2.29. On June 30th they issued a News Release the focus of which was their licensing of RGBP's NR2F6 Patent coupled with their proprietary drug delivery systems for treating various disorders including pancreatic cancer and colon cancer.

https://finance.yahoo.com/news/oncology-pharma-inc-entering-next-120000837.html

In retrospect, Oncology Pharma acquired RGBP's NR2F6 Patent on April 7, 2021. The prior trading day (April 6th) its PPS was $24.99. On April 7th their PPS jumped to $26. Subsequently, their PPS began rising DAILY throughout April hitting $40.37 on April 29th, UP $15.38 relative to their immediate pre-acquisition date (April 6th) of RGBP's Patent.

The take away?? Upon a PR release of RGBP's Patent officially entering Phase I Clinical Trials, that by itself should cause the PPS of BOTH RGBP & Oncology Pharma to jump and begin a steady consistent rise.

Subsequently, any positive PR releases of its progress, including transitioning into Phase II-III, will predictably cause their PPS to continue rising. Just look at how Oncology Pharma's PPS began a steady rise immediately AFTER the news that they acquired RGBP's Patent. There's a reason for this by "those in the know" of what that means.

Keep in mind that by the time of the final phase of Clinical Trials (Phase IV), the candidate drug has already received FULL FDA approval for use in the general population relative to its intended treatment applications. Phase I-III is for efficacy & safety testing only. Phase IV is for drug branding (name selection) and post-marketing surveillance and at that point it is already being prescribed by physicians and administered to patents.

My Point??? This Patent is already in the BAG! If not, it would NOT of been FDA approved for entering clinical trials. WHY? Only 1 in 10,000 Patent applications for an IND get approved by the FDA for entering clinical trials, meaning they are near certain that the limited few they approve will likely transition successfully through all Phases and will be effective pharmaceuticals for disease treatment.

Statistically, less than 50 Patent Applications to the FDA out of 10,000 make it to market annually.

This information arises out of my 30+ Year career as an experienced Clinical Trials M.D. that has worked with several Big Pharmas in bringing their candidate drug Patents to Market.

I hope all the above is helpful to those in this play and/or are considering investing in RGBP.

Be well and prosper...